He will then say he addressed the criticisms in his podcast, which is the best way I know to make sure no one ever hears about it.
-
-
Show this threadThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
where did he pull these fractions from? the stated p value? or was he just using them as a figure of speech? I was really confused to read that tweet.
- End of conversation
New conversation -
-
-
I don’t understand all the critiques of his tweet. Just like Emory football is undefeated (they don’t have a team), @VPwnd_fan has never led a failed trial (or a successful trial for that matter). Those who do not do cannot fail.
-
TIL that the @VPwnd_fan account exists, and I'm grateful to you for that. Thank you.

- Show replies
New conversation -
-
-
Im not a Dr. and have a fairly reasonable understanding of bio. & I have a question about this. It seems that Dr. Prasad is arguing for a low dose regimen of Dex, and that if the study out of the UK is peer reviewed and accurate, then the benefit outweigh the risks (1/1)
-
I understand that Dex. is a regularly prescribed steroid/Anti-inflammatory. If he is wrong, what are the risks of giving a low dose regimen to a COVID pt, and then finding out the study was flawed/wrong/etc? (2/2)
End of conversation
New conversation -
-
-
I’d agree with you except steroids have a pretty strong track record of improving patient-oriented outcomes in ARDS - less vent days, shorter ICU stay, and (according to DEXA-ARDS) lower mortality. No decision in the ICU is a perfect one....
-
...you’re always choosing between probabilities. The odds that you do treat with steroids and turns out they don’t work or are harmful is low, the odds that you wait and 1 out of every 8 patients you see in the next two months dies without them is higher....
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
